KRAS and colorectal carcinoma: Since genomic profiling is essential for therapy in CRC, there have been several attempts to explore the potential role of radiomics in this context by developing radiogenomic models able to predict genomic mutations such as KRAS, BRAF and MSI status and enhance decision-making and patient outcomes.